Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Balance Sheet

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

As of 2026-09-30

Balance Sheet

Swipe to see the full flow
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Balance SheetBalance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.Current liabilities$1.30 BCurrent assets$800.00 MLiabilities$1.39 BAssets$1.33 BNon-current liabilities$91.00 MNon-current assets$532.00 MShareholders' deficit−$60.00 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsAccounts receivable, net of allowances of $3 (2026) and $4 (2025)InventoriesOther current assetsPrepaid expensesCurrent tax receivableDeferred tax assetsProperty, plant and equipment, netLong-term investmentsOther noncurrent assetsOperating lease right of use assets, netGoodwill and other intangible assets, netAccrued rebates and product returnsCurrent portion of long-term debtAccounts payable and accrued expensesIncome taxes payableAccrued litigation settlement expenses, currentOperating lease liabilities, currentAccrued litigation settlement expenses, noncurrentOther noncurrent liabilitiesOperating lease liabilities, noncurrentAccumulated deficitAccumulated other comprehensive lossAdditional paid-in capitalCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesShareholders' deficitShareholders' deficitCash and cash equivalentsCash and cash equivalents$305.00 MAccrued rebates and product returnsAccrued rebates and product returns$548.00 MCurrent liabilitiesCurrent liabilities$1.30 BCurrent assetsCurrent assets$800.00 MAccounts receivable, net of allowances of $3 (2026) and $4 (2025)Accounts receivable, net$273.00 MCurrent portion of long-term debtCurrent portion of long-term debt$488.00 MInventoriesInventories$149.00 MLiabilitiesLiabilities$1.39 BOther current assetsOther current assets$40.00 MAccounts payable and accrued expensesAccounts payable and accrued expenses$181.00 MAssetsAssets$1.33 BPrepaid expensesPrepaid expenses$21.00 MIncome taxes payableIncome taxes payable$63.00 MAccrued litigation settlement expenses, currentAccrued litigation settlement expenses, current$14.00 MCurrent tax receivableCurrent tax receivable$13.00 MOperating lease liabilities, currentOperating lease liabilities, current$7.00 MDeferred tax assetsDeferred tax assets$288.00 MAccrued litigation settlement expenses, noncurrentAccrued litigation settlement expenses, noncurrent$42.00 MNon-current liabilitiesNon-current liabilities$91.00 MOther noncurrent liabilitiesOther noncurrent liabilities$42.00 MProperty, plant and equipment, netProperty, plant and equipment, net$175.00 MNon-current assetsNon-current assets$532.00 MShareholders' deficitShareholders' deficit−$60.00 MOperating lease liabilities, noncurrentOperating lease liabilities, noncurrent$6.00 MLong-term investmentsLong-term investments$27.00 MOther noncurrent assetsOther noncurrent assets$27.00 MAccumulated deficitAccumulated deficit−$197.00 MAccumulated other comprehensive lossOther comprehensive loss−$26.00 MOperating lease right of use assets, netOperating lease right of use assets, net$12.00 MAdditional paid-in capitalAdditional paid-in capital$163.00 MGoodwill and other intangible assets, netGoodwill and other intangible assets, net$2.00 M
Chart details

Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Balance Sheet

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

Assets
1,332,000,000 US dollars
Current assets
800,000,000 US dollars
Non-current assets
532,000,000 US dollars
Liabilities
1,392,000,000 US dollars
Current liabilities
1,301,000,000 US dollars
Non-current liabilities
91,000,000 US dollars
Shareholders' deficit
negative 60,000,000 US dollars
Cash and cash equivalents
305,000,000 US dollars
Accounts receivable, net of allowances of $3 (2026) and $4 (2025)
273,000,000 US dollars
Inventories
149,000,000 US dollars
Other current assets
40,000,000 US dollars
Prepaid expenses
21,000,000 US dollars
Current tax receivable
13,000,000 US dollars
Deferred tax assets
288,000,000 US dollars
Property, plant and equipment, net
175,000,000 US dollars
Long-term investments
27,000,000 US dollars
Other noncurrent assets
27,000,000 US dollars
Operating lease right of use assets, net
12,000,000 US dollars
Goodwill and other intangible assets, net
2,000,000 US dollars
Accrued rebates and product returns
548,000,000 US dollars
Current portion of long-term debt
488,000,000 US dollars
Accounts payable and accrued expenses
181,000,000 US dollars
Income taxes payable
63,000,000 US dollars
Accrued litigation settlement expenses, current
14,000,000 US dollars
Operating lease liabilities, current
7,000,000 US dollars
Accrued litigation settlement expenses, noncurrent
42,000,000 US dollars
Other noncurrent liabilities
42,000,000 US dollars
Operating lease liabilities, noncurrent
6,000,000 US dollars
Long-term debt, less current portion
0 US dollars
Additional paid-in capital
163,000,000 US dollars
Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 118 (2026) and 125 (2025)
0 US dollars
Accumulated deficit
negative 197,000,000 US dollars
Accumulated other comprehensive loss
negative 26,000,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
  • The filed current assets lines add up to $801.00 M and the current assets total is $800.00 M; the $1.00 M difference is within the rounding of the filed amounts.
  • The filed non-current assets lines add up to $531.00 M and the non-current assets total is $532.00 M; the $1.00 M difference is within the rounding of the filed amounts.
  • The filed non-current liabilities lines add up to $90.00 M and the non-current liabilities total is $91.00 M; the $1.00 M difference is within the rounding of the filed amounts.
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!